Browsing Tag


New Preventative Treatment for Migraine Sufferers

A recent trial of a humanised monoclonal antibody has shown potential in the preventative treatment of migraines in chronic migraine sufferers. It is hoped that the drug can be used to treat the notoriously debilitating Cluster headaches. Fremanezumab is in the class of drugs that block the CGRP pathway. Other drugs with this mechanism of action already on the market include Eptinezumab, Erenumab and Galcanezumab. The new treatment centres around the use of a humanised monoclonal antibody known as Frumenezumab to target…

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More